We continue to believe that NRP104 has a best-in-class clinical profile and blockbuster market potential, given its improved safety profile compared to other stimulants.

Andrew Forman

Related Quotes

The market share for generics, which is already 54 percent [of prescriptions] should increase significantly,

— Andrew Forman

a million and one different vendors. Unless they test everyone, the findings are meaningless.

— Andrew Forman

For the remaining players it's going to be tough. It's tough already.

— Andrew Forman

The psychology of it -- $100 -- it seems like a lot. That's a nice problem to have. So few companies are doing very, very well.

— Andrew Forman

You're talking about very rapid adoption.

— Andrew Forman